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Edited by Jesus AvilaAbstract RK13 cell lines generated to express bovine PrPC
with a four extra octarepeat insertional mutation (Bo-
10ORPrPC) show partially insoluble PrPC and lower rates of
cell growth when compared to either the same cells expressing
wild type Bo-6ORPrPC or the original RK13 cell line. The
expression of Bo-10ORPrPC in cell cultures was also associated
with changes in cell size and reorganization of the actin cytoskel-
eton. This last process was reversed by Clostridium diﬃcile tox-
in-B, a speciﬁc inhibitor of small GTPase proteins. Further, in
clones expressing Bo-10ORPrPC, increased proportions of cells
at cell cycle stage G2/M were observed. Proteasome inhibitors
caused a further expansion of G2/M-stage cells that was more
marked in cell lines expressing Bo-10ORPrPC than those
expressing Bo-6ORPrPC, while this eﬀect was minimal or null
in the original RK13 cell line. Hence, the presence of Bo-
10ORPrPC in RK13 cells promotes cell cycle arrest at G2/M,
and the eﬀect is ampliﬁed by proteasome inhibition. These ﬁnd-
ings suggest a role for PrPC in cell morphology and cell cycle
regulation, and open new avenues for understanding the mecha-
nisms underlying PrP mutation-associated diseases.
 2006 Federation of European Biochemical Studies. Published
by Elsevier B.V. All rights reserved.
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Prion diseases or transmissible spongiform encephalopathies
are neurodegenerative disorders characterized by extensive
neuronal apoptosis and a build up of PrPSc, a misfolded form
of the cellular prion protein (PrPC) [1–4]. Prion diseases such
as scrapie in sheep, bovine spongiform encephalopathy
(BSE) in cattle, and Creutzfeldt–Jakob disease in man, may
be of an infectious origin. Inherited prion diseases has been
only described in humans and have been associated with both
point mutations and an increased number of octarepeats in the
PrPC open reading frame (ORF) [5–8]. The cellular mechanismAbbreviations: PrPC, cellular prion protein; OR, octapeptide repeat;
Bo-10ORPrPC, bovine PrPC with a four extra octarepeat insertional
mutation; Bo-6ORPrP, normal Bo-PrPC; ORF, open reading frame;
Tg, transgenic
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doi:10.1016/j.febslet.2006.06.054by which mutations in the prion protein gene causes neurolog-
ical dysfunction is unknown. It has been proposed that neuro-
nal death can be triggered by accumulation of PrP in the
cytosol due to impairment of proteasomal degradation of mis-
folded PrP molecules retrotranslocated from the endoplasmic
reticulum [9].
In previous work, transgenic (Tg) mouse models expressing
PrPC with four or nine octapeptide insertional mutations
showed a prion-like disease characterized by gliosis, and apop-
totic loss of cerebellar granule cells [10,11] analogous to the
disease observed in patients with a four extra repeat mutation
in the PrPC gene [6]. Furthermore, it has been shown that PrPC
with insertional mutations acquires special properties that may
be reminiscent from PrPSc: ligand-binding, oxidative attack
susceptibility, detergent insolubility, increased protease resis-
tance, and aggregation capacity [5,12–15]. These properties
suggest that insertional mutations confers neurotoxic proper-
ties (but not infectious) in PrP as showed by the neurodegera-
tive phenotype associated with these mutations [10,11,16]. It is
thus clear that a greater understanding of PrPC structure and
the eﬀects of adding octarepeats to its coding region are
required.
The present study was designed to explore prion related dis-
orders of inherited origin using an experimental cell model. For
this purpose, we used an epithelial RK13 cell line with no
detectable PrPC expression to generate two diﬀerent cell lines
expressing the normal Bo-PrPC (Bo-6ORPrP) or a mutated
form containing four extra octapeptide repeats (Bo-10ORPrP).
Bo-10ORPrP acquired diﬀerent biochemical properties and
modiﬁed the RK13 cell phenotype by disrupting the reorgani-
zation of the actin cytoskeleton and normal cell cycle regula-
tion. These ﬁndings open a new avenue for understanding the
role of PrPC in cellular homeostasis.2. Materials and methods
2.1. Cell line and culture conditions
The rabbit kidney cell line RK-13 (WT), obtained from ATCC (CCL
37), was derived from kidney cells from a 5-week-old rabbit. These
cells were cultured in Dulbecco’s modiﬁed Eagle’s minimum-essential
medium (Grand Island Biological Company-Bethesda Research Labo-
ratories (GIBCO-BRL), Bethesda, MD, USA) supplemented with 5%
fetal bovine serum (Hyclone, Salt Lake City, UT, USA), 2 mM L-glu-
tamine, 1% non-essential amino acids and 100 U/ml penicillin. Cell
lines were cultured in a humidiﬁed atmosphere containing 5% CO2
in air at 37 C. Cell viability was determined by the trypan blue exclu-
sion method.lished by Elsevier B.V. All rights reserved.
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The open reading frame (ORF) of the bovine PrP gene was obtained
by PCR ampliﬁcation from genomic bovine DNA using primers that
create a NotI restriction enzyme site adjacent to the translation start
codon (5 0-GCGGCCGCATCATGGTGAAAAGCCACATAG-3 0)
and the stop site (5 0-GCGGCCGCCTATCCTACTATGAGAAAA-
ATG-3 0). The 5 0 primer also included Kozak sequences [17]. The
PCR fragment was subcloned into a T-tailed vector and the insert
was sequenced, conﬁrming six copies of the octarepeat sequence and
no changes in the amino acid sequence inferred from previously se-
quenced bovine PrP genes (GenBank accession number AF455119).
The four extra octarepeats were introduced into the six-octarepeat
bovine PrP gene as follows: 5 0-CATGGAGGTGGCTGGGGCCA-
GCCC-3 0 and 5 0-CATGGGGCTGGCCCCAGCCACCTC-3 0 primers
were used to obtain a tandem of four artiﬁcial octarepeats containing
ends compatible with the NcoI restriction enzyme site. The PrP ORF
was partially cut with the NcoI to avoid eliminating the native OR,
and the tandem of four artiﬁcial octarepeats containing compatible
extremes to NcoI was inserted. These plasmids were digested with NotI
and inserted into the NotI site of pCMV plasmid to obtain the ﬁnal
plasmids designated as pCMVbo6ORPrP and pCMVbo10ORPrP.2.3. Transfecting the RK13 cells
RK13 cells were cultured on 6-well sterile plastic trays (Nunc). At
70% conﬂuence, cells were transfected with the above mentioned endo-
nuclease digested constructs and cotransfected with pKneo plasmid
(Stratagene). After selection with geneticin (G418; 500 lg/ll), cells
were subcloned and analyzed by Western blotting and indirect immu-
noﬂuorescence. Two clones showing diﬀerent levels of PrP expression
were selected for each construct: two clones expressing the normal
Bo-6ORPrPC (clones 8 and 2.4) and two clones expressing the mutant
Bo-10ORPrPC (clones 3.1 and 4.1).2.4. Detecting PrP by Western blotting
Cells were seeded (30000 cells/well) in 6-well sterile plastic trays.
Upon conﬂuence, cells were harvested with PBS 0,05% EDTA and
after 5000 · g centrifugation 5 min, the pellet was resuspended in
potassium buﬀer 20 mM. The protein concentrations of cell extracts
were determined by the BCA protein assay (Pierce). 20 lg of protein
were used in a 90 ll ﬁnal volume. 10 ll of 10% SDS was added to every
sample and boiled during 10 min. Then, four volumes of deglycosyla-
tion buﬀer (20 mM potassium buﬀer, 30 mM EDTA, 0,8% NP-40,
1.2% Triton X-100, 1.2% b-mercaptoethanol) were added and divided
in two tubes. One of the two tubes was treated with 5 U of N-glycosi-
dase F (NGF) (Roche). After incubation over night, 4 vol. of cold
methanol were added and samples were incubated 2 h at 70 C. Fi-
nally, they were centrifuged during 30 min at 20000 · g and the pellet
was resuspended in SDS sample loading buﬀer and then boiled for
10 min before loading on an SDS/12% polyacrylamide gel. Anti-PrP
mAbs 6H4 (Prionics) or 2A11 [18] were used at 1/5000 and 1/1000 dilu-
tions, respectively for immunoblotting. Immunocomplexes were de-
tected using horseradish peroxidase conjugated anti-mouse IgG
(Sigma Chemical Co.). Immunoblots were developed with enhanced
chemiluminescence ECL (Amersham).
2.5. Detecting PrP by ﬂow cytometry
Cells were harvested with 0.5 M EDTA in PBS, washed twice in PBS
and blocked in 1· Perm Wash buﬀer (Pharmingen). To obtain perme-
abilized intact cells, cells were incubated with 2% formaldehyde in PBS
for 20 minutes at 4 C and washed three times in 1· Perm Wash buﬀer.
All cellular samples, permeabilized and non permeabilized cells, were
then incubated for 60 min at 4 C with the 2A11 anti-PrP mAb
(1:2000), and then with Alexa Fluor 488 goat anti-mouse IgG (A-
11029, Molecular Probes) (1:200). Finally, the cells were examined
by FACScan (Becton Dickinson, USA) at excitation and emission
wavelengths of 475 and 520 nm, respectively. In each analysis, 5000
cells were examined.
2.6. Triton/Doc insolubility and proteinase-K sensitivity assay
Detergent insolubility of Bo-6ORPrPC and Bo-10ORPrPC expressed
in RK13 cell lines was tested following the procedure previously de-
scribed [19] with minor modiﬁcations. Conﬂuent cells (5 · 106 cells/
sample) were lysed in Triton/Doc buﬀer (0.5% TX-100, 0.5% Na-deoxycholate, 150 mM NaCl, and 100 mM Tris, pH 7.5) for 20 min
at 4 C and PrPC was quantiﬁed in each case by Western blot. Nine
volumes of the same buﬀer (ice-cold) were added to the whole cell ex-
tracts and equivalent amounts of PrPC were centrifuged (1000 · g,
10 min, 4 C). The supernatants were centrifuged at 25000 · g for
60 min at 4 C (Hettich zentrifugen, Germany). PrPC was recovered
in the supernatants by methanol precipitation, while the pelleted frac-
tions were resuspended in the same buﬀer (containing 0.5% TX-100,
0.5% Na-deoxycholate). Insoluble PrPC fractions were treated with
2 lg/ml of proteinase K (PK) for 1 h at 37 C. All fractions whether
PK treated or not were analyzed by SDS–PAGE/Western blotting
using 2A11 anti-PrP mAb as described above.
2.7. Total cell counts and viable cell numbers
Total cell counts were performed using a haemocytometer and viable
cells were counted after trypan blue exclusion (T 8154, Sigma). An
equal volume of 2· trypan blue buﬀer was added to all samples
(10 lg total protein per sample) and non-viable and viable cells quan-
tiﬁed in each one by observation under the light microscope.
2.8. Histochemical detection of intracellular a-actin ﬁlaments
Cells were grown on sterile glass coverslips. After washing twice in
PBS, the cells were incubated in 70% methanol in water for at least
1 h at 4 C. This ﬁxative was removed and cells were washed twice
in PBS. Subsequently, the cells were incubated for 30 min with an
anti-a-actin mAb (MS-1296, LabVision corporation) (1:2000) followed
by the Alexa Fluor 488 goat anti-mouse IgG (A-11029, Molecular
Probes) (1:200). Finally, the cells were examined under a ﬂuorescence
microscope (Nikon Phase Contrast-2 ELWD 0.3) at excitation and
emission wavelengths of 475 and 520 nm, respectively, and images cap-
tured and analysed using a digital camera (Hamamatsu ORCA-ER
digital camera C4742-95).
2.9. Detecting actin and/or nuclear DNA by ﬂow cytometry
Propidium iodide (P-4170, Sigma), like ethidium iodide, intercalates
with the nucleic acid helix and produces an increase in ﬂuorescence
detectable using excitation and emission wavelengths of 475 and
615 nm, respectively. The Alexa-488 conjugated antibody against a-ac-
tin is nevertheless ﬂuorescent per se using excitation and emission
wavelengths of 475 and 525 nm, respectively. Both indicators could
be used together in the same sample. To determine a-actin levels or/
and nuclear DNA contents, cells were trypsinized and then neutralized
in DMEM medium. After washing twice in PBS, the cells were ﬁxed
using 70% methanol at 4 C for at least an hour. After incubation
(30 min at 4 C) with an anti-a-actin mAb (1:2000), the cells were incu-
bated with the Alexa Fluor 488 goat anti-mouse IgG (A-11029, Molec-
ular Probes) (1:200). Finally, 5 rmug/ml RNAse and 10 lg/ml
propidium iodide were added at room temperature for at least for
30 min. These samples were measured using a FACScan ﬂow cytome-
ter (Becton Dickinson, San Jose, CA) with excitation and emission
wavelengths set at 475 and 525/615 nm, respectively. In each analysis,
5000 events were recorded.
2.10. Proteasome inhibition with MG132
For proteasome inhibition experiments, cells were seeded at 30000
cells/well in 6 well plates, three wells per cell line. Twenty-four hours
later cells were harvested and medium replaced with complete mini-
mum essential medium containing 5 lM of MG132 and the cells incu-
bated for 0, 12 or 24 h at 37 C. After treatment, cells were stained with
10 lg/ml propidium iodide and 5 lg/ml RNase A at 37 C in dark and
their cell cycle stages determined by ﬂow cytometry.
Proteasome activity was measured in all cell lines before the addition
of any inhibitor using the Proteasome-Glo Cell-Based Assay (Prome-
ga) and analyzed with the LUMIstar Galaxy Luminometer (BMG).3. Results
3.1. Expression of normal and mutated forms of bovine PrPC in
the RK13 cell line
A set of cell lines were obtained from the RK13 cell line,
from which we selected groups of cell lines according to PrPC
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and 2.4) and two clones expressing Bo-10ORPrPC (clones 3.1
and 4.1). As shown in Fig. 1A, bovine PrPC protein expression
was examined in these cell lines by Western blotting using the
2A11 monoclonal antibody. The blots indicated higher expres-
sion levels in clones 2.4 and 3.1 than in clones 4.1 and 8. No
PrPC expression could be detected in the wild type RK13 cell
line as previously described [20]. To verify the diﬀerences in
molecular weight between the Bo-6ORPrPC and Bo-
10ORPrPC proteins, PrPC glycans were removed by endogly-
cosidase (PNGaseF) digestion. As expected, the proteins
showed diﬀerent relative mobilities (Fig. 1A).
3.2. Subcellular localization of Bo-6ORPrPC and
Bo-10ORPrPC
The subcellular localizations of Bo-6ORPrPC and Bo-
10ORPrPC expressed in RK13 cell lines were analyzed by ﬂow
cytometry in permeabilized and non-permeabilized cells using
the PrP speciﬁc mAb 2A11 as described in Section 2. WhileClon 8
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Fig. 1. Analysing the expression of wt Bo-6ORPrPC and mutated Bo-10ORP
were seeded at a density of 30000 cells/well in 6-well sterile plastic trays. Upon
(NGF). All fraction, NGF-treated or not, were analysed by Western blotting
were loaded on each lane. The data shown were obtained from one represe
molecular mass (MW) appears in kilodaltons. (B) Flow cytometry analysis o
2A11. Histograms corresponding to PrPC ﬂuorescence distribution (X-axis:
observed in one representative experiment out of three producing similar resno labelling was detected in the original RK13 cell line, all
clones expressing either Bo-6ORPrPC (clones 8 and 2.4) or
Bo-10ORPrPC (clones 3.1 and 4.1) showed intense labelling
for PrP (Fig. 1B). No signiﬁcant diﬀerences were observed
when compared the ratio of cell surface PrP (non-permeabili-
zed)/total PrP (permeabilized cell) in the diﬀerent cell lines.
These results indicate that both Bo-6ORPrPC and Bo-
10ORPrPC protein expressed in RK13 have a similar cellular
distribution. Both proteins showed a preferential intracellular
location but also occur at the cell surface. This ﬁnding was
conﬁrmed by immunoﬂuorescent microscopy (data not
shown).
3.3. Biochemical properties of Bo-10ORPrPC expressed in
RK13 cell lines
In a previous study [11], we noted that Bo-10ORPrPC
expression in transgenic mice gave rise to a build up of an
insoluble and partly proteinase K-resistant form of PrPC in
the brain. To establish whether RK13-derived Bo-10ORPrPCClon 2.4
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ntative experiment out of three yielding identical results. The relative
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ults.
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extracts were analysed as indicated in Section 2. No protease
resistant PrP could be found in any cell line tested under the
conditions used in this assay. However, Bo-10ORPrPC protein
was found to be partially insoluble in non-denaturing deter-
gent extracts, while Bo-6ORPrPC protein was only found in
the soluble fraction (Fig. 2). These results are consistent with
the properties of these same proteins expressed in transgenic
mice [11].
3.4. RK13 cell lines expressing Bo-10ORPrPC show an increased
cell size but not a pro-apoptotic phenotype
In transgenic mouse models expressing PrPC with four or
nine octarepeat insertional mutations [10,11], the neuropatho-
logical changes produced are characterized by PrP deposition
in diﬀerent brain areas, gliosis, and loss of cerebellar granule
cells. Thus, apoptotic cell death is a normal phenomenon in
these transgenic mice. To establish whether Bo-10ORPrPC
could give rise to a pro-apoptotic phenotype upon expression
in cell cultures, we subjected cells to diﬀerent apoptotic stimuli
(Supplemental ﬁgure 1A). It was found that hydrogen perox-
ide, tumour necrosis factor alpha, and serum deprivation in-
duced similar mortality rates in all cell lines independently of
the PrPC expressed. Thus, none of these stimuli led to a PrPC
dependent pro-apoptotic phenotype.
In the search for phenotypic diﬀerences between cell lines
expressing Bo-6ORPrPC and Bo-10ORPrPC, we then exam-
ined cellular senescence in the cultures. As shown in Supple-
mental ﬁgure 1B, no signiﬁcant diﬀerences in the times to
senescence were found among the cell lines, although lower
absolute cell numbers were attained in Bo-10ORPrPC-
expressing cells than in Bo-6ORPrPC-expressing cells or ori-
ginal RK13 cells (Supplemental ﬁgure 1A). To investigate
these diﬀerences in the cell populations, cells were grown
on culture plates and cellular morphology examined by stain-
ing for a-actin. As revealed in Fig. 3A, in clones 3.1 and 4.1
expressing Bo-10ORPrPC, several larger cells appeared,
which were absent from the wild type RK13 or Bo-
6ORPrPC-expressing cell lines (clones 8 and 2.4). This larger
cell size observed among cells expressing Bo-10ORPrPC ap-
peared in normal growth conditions. However, after trypsinS P P       S       P     P       S    
PK
(-)
PK
(+)
PK
(-)
PK
(+)
PK
(-)
Clone 8 Clone 2.4 Cl
RK13 Bo-6ORPrPC
Fig. 2. Insolubility and proteinase-K sensitivity of wt Bo-6ORPrPC and muta
fractions from cell lysates in Triton/Doc buﬀer were obtained after centrifug
fractions were treated or not treated with 2 lg/ml of proteinase K (PK) fo
Western blotting using the 2A11 anti-PrP mAb. The data shown were obtain
results.treatment of the cell culture monolayer, each cell line dis-
played similar cell morphology, both by light microscopy
and ﬂow cytometry (Fig. 3B). Thus, the cell size diﬀerences
observed only appeared under adherence on culture plates
but not after trypsin treatment.
To establish whether the altered cell morphology was a bio-
logical process directly related to the actin cytoskeleton, we
also quantiﬁed the amount of actin ﬁlaments in each cell line
by ﬂow cytometry using anti-a-actin antibodies. Actin contents
failed to vary signiﬁcantly among the cell lines (Fig. 3B). Given
these similar amounts of actin in Bo-10ORPrPC – and Bo-
6ORPrPC-expressing cells as well as in the original RK13 cells,
the larger cell sizes observed in the Bo-10ORPrPC – producing
clones could be related to the presence of cytoskeleton archi-
tecture regulators. However, we can not discard the possibility
that the absence of cell size diﬀerences after trypsin treatment
could be due to the low number of enlarged cells poorly repre-
sented in the pool of cells analyzed.
3.5. GTPase protein inhibitors recover the normal phenotype of
Bo-10ORPrP-expressing cells
The small family of GTPases, Rho, Cdc42 and Rac1, com-
prises the most important regulators of the actin cytoskeleton,
aﬀecting cell shape and movement. In order to decipher if
small GTPases could be regulating the increased cell size ob-
served in the Bo-10ORPrPC-expressing clones, we incubated
cell monolayers with Clostridium diﬃcile toxin-B. As shown
in Fig. 4, the enlarged cell phenotype of the Bo-10ORPrPC-
expressing clones was reversed after incubation with the toxin.
These small GTPase proteins therefore seem to play a role in
increasing cell size in these cell lines. Interestingly, nuclei were
larger in the Bo-10ORPrPC-expressing clones than in the
remaining cell lines. These observations suggest that Bo-
10ORPrPC-expressing clones have larger amounts of DNA,
which is indicative of cell cycle dysregulation.
Clones expressing Bo-10ORPrPC showed increased propor-
tions of cells at the G2/M stage and this eﬀect is ampliﬁed
by proteasome inhibition. To explore whether the cell cycle
was altered in the Bo-10ORPrPC-expressing cells, DNA was
stained with propidium iodide and subjected to ﬂow cytometry
analysis. An approximate 20% increase in the number of G2/M    P      P       S P       P MW
52
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r 1 h. All fraction, PK-treated or not, were analyzed by SDS–PAGE/
ed from one representative experiment out of three producing identical
Fig. 3. Analysis of the morphology-complexity and amount of actin in RK13 cells expressing wt Bo-6ORPrPC or mutated Bo-10ORPrPC. (A) Cells
lines were seeded (30000 cells/well) in 6-well sterile plastic trays. Upon conﬂuence, the medium was replaced with serum-free minimum essential
medium, and the cells incubated with the anti-actin mAb followed by the Alexa Fluor 488 goat anti-mouse IgG as described in Section 2. Each cell
line was visualized and analyzed by ﬂuorescence microscopy. Representative ﬁelds are shown at a magniﬁcation of 25·. Note the enlarged cells
indicated by white arrows. (B) Cell lines were cultured as described above but upon conﬂuence they were trypsinized and neutralized using medium.
Morphology-complexity was assessed in each cell line by light microscopy (column 1) and ﬂow cytometry (X-axis: FSH, Y-axis: SSC) (column 2).
Representative light microscopy ﬁelds are shown at a magniﬁcation of 25·. Trypsinized cells were also used to evaluate the total actin amounts by
ﬂow cytometry (column 3) as described in Section 2. Histograms show the actin ﬂuorescence distribution (X-axis: actin ﬂuorescence by Alexa 488,
Y-axis: number of cells) recorded in one representative experiment out of three.
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when compared to both Bo-6ORPrPC-expressing and original
RK13 cells (Fig. 5). This observation clearly points to cell cycle
dysregulation.
It has been established that proteasome inhibition often
accompanies protein aggregation in cells expressing PrPC
[21]. Thus, to determine if inhibition of the proteasome com-
plex could enhance the expansion of G2/M cells expressing
boPrPC, cells were incubated with MG132. As represented
in Fig. 6, the proteasome inhibitor induced slight G2/M cell
expansion in the original RK13 cell line (4% and 9% after
12 and 24 h, respectively), and relatively increased G2/M cell
expansion in the clones expressing Bo-6ORPrPC (12–30%)
and Bo-10ORPrPC (40–55%). To determine whether this ef-
fect is caused by an inhibition of proteasomal activity by the
expression of PrPC or not we evaluated the proteasomal
activity in the diﬀerent cell lines before the addition of
MG132 inhibitor. The results (supplemental ﬁgure 2) showed
no signiﬁcant diﬀerences in proteasomal activity between the
diﬀerent cell lines allowing us to exclude the possibility of an
inhibition of proteasome activity by the expression of PrPC.
These data point to an expansion of G2/M cells promoted
by proteasome blocking in all the cell lines (Fig. 6)
and an ampliﬁed eﬀect of proteasome inhibition in the
presence of Bo-PrPC protein, especially mutated PrPC
(Bo-10ORPrP).4. Discussion
In this study, we used a cell model derived from the rabbit
epithelial cell line RK13 expressing diﬀerent forms of PrPC:
two clones expressing the wild type Bo-6ORPrPC (clones 8
and 2.4) and two clones expressing the mutant Bo-10ORPrPC
(clones 3.1 and 4.1). The RK13 cell line was chosen on the
grounds that: (i) these cells express no detectable protein levels
of endogenous rabbit PrPC, thus reducing the risk of interfer-
ence with the activity of the transfected boPrPC; and (ii) this
cell line has already been used as an adequate background
for the propagation of ovine prions [20]. In the present study,
we observed that cells expressing the partially insoluble
Bo-10ORPrPC displayed an increased cell size and an ex-
panded G2/M-stage cell compartment. The data reported here
provide insight into the possible mechanisms used by this
peptide to promote disease.
In the RK13 cell line, the mutant Bo-10ORPrPC protein was
found to be partially insoluble, while the wild type
Bo-6ORPrPC protein was soluble. This ﬁnding correlates well
with previous observations in transgenic mice expressing bo-
vine PrP, in which the addition of four extra octapeptide re-
peats (Bo-10ORPrP) rendered a more insoluble PrP [11]. The
reason for this increased insolubility remains to be established.
It has been suggested that an increased number of OR causes
enhanced aggregation of the mutant PrP protein in the
Fig. 4. Eﬀect of the Clostridium diﬃcile toxin-B on cell morphology.
Cell lines were seeded (30000 cells/well) in 6-well sterile plastic trays.
Upon conﬂuence, the medium was replaced with complete minimum
essential medium containing 10 ng/ml of Clostridium diﬃcile toxin-B
and incubated for 3 h at 37 C. After treatment, morphological
changes in the RK13 cell lines were assessed by incubation with the
anti-actin mAb followed by Alexa Fluor 488 goat anti-mouse IgG as
described in Section 2 and light microscopy. The micrographs shown
are representative of at least three independent experiments. Repre-
sentative ﬁelds are shown at a magniﬁcation of 40·. Note the enlarged
cells indicated by arrows.
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Fig. 6. Eﬀects of proteasome inhibitors on the cell cycle stages of
RK13 cells expressing wt Bo-6ORPrPC or mutated Bo-10ORPrPC.
Cell lines were harvested when they reached 50% conﬂuence. The
medium was then replaced with complete minimum essential medium
containing 5 lM of MG132 and the cells incubated for 0, 12 or 24 h at
37 C. After treatment, cells were stained with 10 lg/ml propidium
iodide and 5 lg/ml RNase A at 37 C in dark and their cell cycle stages
determined by ﬂow cytometry as indicated for Fig. 5. Data are
represented as histograms and bars to aid comprehension. The data
shown are representative of at least three experiments.
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case, we propose that the build up of partially insoluble Bo-
10ORPrP could be a consequence of impaired proteasomal
activities increasing the life span of PrP in the cell. This
would in turn favour the appearance of partially insoluble
Bo-10ORPrPC. Thus, the appearance of partially insoluble
Bo-10ORPrPC could hinder the elimination of PrPC by the cell
proteasome pathway.
The expansion of G2/M-stage cells observed in all our cell
lines was ampliﬁed by proteasome inhibition in a PrPC
dependent manner. Thus, the subset of G2/M-stage cells in
the native RK13 cell lines was unaﬀected by the proteasome
inhibitor MG132. In contrast, G2/M cell expansion was
ampliﬁed in clones expressing the wild type Bo-6ORPrPC
and ampliﬁed further still in the clones expressing the mutant
protein Bo-10ORPrP. These ﬁndings seem to suggest that the
presence of modiﬁed PrPC (Bo-10ORPrP) with a tendency to-
wards aggregation seems to interfere with normal cell cycle
regulation. To date, a role for PrPC signalling in cell cycle
control has not yet been reported. However, it is known that
proteasome inhibitors induce an enrichment of G2/M-stage
cells [26]. Several authors have shown that the overexpression
of both PrPC and insertionally mutated PrPC reduce the life-
span of animal models [11,26,27]. Moreover, an expansion of
cells at G2/M has been described in the rapid ageing disease
progeria [28]. There are also reports that show a functional
relationship between small GTPase proteins and PrPC
[29,30]. Hence, we could suggest an indirect relationship be-
tween G2/M-stage cell expansion and PrP
C through small
GTPase proteins. In porcine aortic endothelial cells, G2/M
cell expansion occurs when the constitutive active forms of
Rac and Cdc42 are induced [31], promoting Ras over expres-
sion [32]. Collectively, our ﬁndings could support the idea
that PrP may directly or indirectly aﬀect the cell cycle by
its arrest at the G2/M stage.
In our study, cells expressing Bo-10ORPrP showed an in-
creased size. Recovery of the normal phenotype by Clostridium
diﬃcile toxin-B (a speciﬁc inhibitor of small GTPase protein
family members) suggests that the larger cell size could be
caused by a normal GTPase-mediated action on the actin cyto-
skeleton. Nevertheless, the nucleus was relatively larger in
these enlarged cells than normal. This suggests that the cell size
increase occurs after cell cycle arrest at stage G2/M. A relation-
ship between the actin cytoskeleton and PrPC has been indi-
rectly reported by other authors, who indicate strong
interaction between PrPC and cytoskeleton components, such
as b-actin and a-tubulin [33]. In a study focussing on PrP
mRNA and smooth muscle a-actin mRNA in culture-acti-
vated stellate cells, strong correlation was revealed between
both mRNAs [34]. In addition, a speciﬁc interaction has been
noted between the cytoskeletal assembly protein sla1 and the
prion-forming domain of the release factor Sup35 (eRF3) in
Saccharomyces cerevisiae [35]. Finally, toxic PrP-derived pep-
tide (PrP106-126) has been shown to bind to tubulin in cell-free
assays and also to inhibit microtubulin formation mediated by
tau [36]. Thus, we infer a possible functional relationship
between PrP and actin cytoskeleton reorganization.
The increased cell size and the expanded G2/M-stage cell
compartment observed in cells expressing the mutant Bo-
10ORPrP could constitute two overlapping phenomena. In
adherence, the nucleus was relatively larger in these enlarged
cells than normal; while an expansion of cells at G2/M hasbeen observed in solution. This suggests that the cell size in-
crease occurs after cell cycle arrest at stage G2/M, probably
by a stop of mitosis in these mutant cells.
In addition, although it is generally accepted that neuronal
loss is a cardinal feature of prion diseases, the role of apoptosis
in this process has received limited attention. It is known that a
synthetic peptide derived from the PrPC sequence (PrP106–126)
induces the apoptotic death of cultured neurons [37]. Several
transgenic mice expressing mouse PrP with extra octapeptide
insertional mutations have shown granule cell apoptosis, gliosis
and loss of cerebellar granule cells [10,11]. Here, the expansion
of G2/M-stage cells in RK13 clones expressing Bo-10ORPrP
was independent of a pro-apoptotic phenotype. However, it is
known that some pro-apoptotic phenotype inducers including
vincristine, b-catenin, nocodazole, paclitaxel, evodiamine, etc.
render increased proportions of G2/M-stage cells [38–45]. Thus,
our ﬁndings in RK13 cells require conﬁrmation using cultured
nerve cells, in which apoptosis is known to be a feature of prion
diseases.
In conclusion, the data presented indicate that a four extra
repeat mutated PrP in RK13 cells induces changes in cell size
and an expansion in G2/M-stage cells, probably mediated by
a small GTPase protein. Our results suggest that the presence
of the modiﬁed PrPC (Bo-10ORPrP), which has a tendency to
aggregate, seems to interfere with the control of the normal cell
cycle by causing arrest at the G2/M stage. In addition, the
expansion of G2/M-stage cells can be ampliﬁed by proteasome
inhibition in a PrPC dependent manner, suggesting a role for
PrPC in cell cycle regulation.
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